GlobeNewsWire
23 Jun 2026, 12:50 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The FDA provided positive feedback and accepted the Phase 3 registrational protocol for Entera Bio's oral osteoporosis tablet, EB613. — Securing FDA alignment on a Phase 3 design significantly reduces regulatory risk and creates a clear path toward potential commercialization.
+0.80Entera Bio expects to initiate the Phase 3 study in late 2026, with topline results anticipated in the second half of 2028. — Provides investors with a concrete timeline for the next major value-inflection catalyst.
+0.30Recent data from ENDO 2026 shows EB613's single-tablet version has a pharmacokinetic profile comparable to the injectable Forteo. — Clinical proof of equivalence to an established blockbuster (Forteo) increases the probability of Phase 3 success.
+0.30Continue reading
6 related stories
Search tags
The company is leveraging its N-Tab platform to develop additional oral peptide candidates, including EB612 for hypoparathyroidism and EB618 for obesity. — Transforms the company from a single-asset risk to a platform play, increasing its overall valuation and attractiveness for partnerships.
+0.20Which stocks this story touches
The company received positive FDA feedback on its Phase 3 protocol for EB613, establishing a clear regulatory path for a potential first-of-its-kind oral osteoporosis treatment.
Mentioned as a collaborator on multiple promising oral peptide programs for hypoparathyroidism and obesity.
Mentioned as a successful example of the commercial logic for oral peptide medicines.
Mentioned as the manufacturer of Forteo to provide historical context for the active hormone used in Entera Bio's drug.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
11h ago
